Glioblastomas are the most common primary central nervous system tumors in adults, and they remain resistant to current treatments. erbB1 signaling is frequently altered in glioblastomas, suggesting that erbB receptor family members may represent targets for molecular therapy. We performed a comprehensive analysis of erbB receptor and ligand expression profiles in a panel of 9 glioblastomas and compared them to nonneoplastic cerebral tissue containing neocortex and adjacent white matter. Quantitative reverse transcriptionpolymerase chain reaction and Western blot analysis showed that erbB1 signaling and erbB2 receptors exhibited highly variable deregulation profiles in the tumors, with patterns ranging from underexpression to overexpression; in contrast, erbB3 and erbB4 were downregulated. We next performed immunohistochemistry to determine the distribution patterns of erbB receptors among the main neural cell types in the tumors with special reference to the putative tumor stem cell population. Results revealed intertumoral and intratumoral heterogeneity in all 4 erbB expression profiles, but each receptor exhibited a distinct distribution pattern among glial fibrillary acidic protein-, Olig2-, NeuN-, and CD133-positive populations. Although erbB1 immunoreactivity was detected in only small subsets of CD133-positive putative tumor stem cells, erbB3 immunoreactivity was prominent in this population, suggesting that erbB3 may represent a new potential therapeutic target.
INTRODUCTION
Glioblastomas (GBMs) are the most common primary central nervous system (CNS) tumors in adults. They are the most malignant form of glioma (World Health Organization Grade IV) and arise either from the progression of a lower-grade glioma (secondary GBM) or de novo, without any known history of a preceding tumor (primary GBM). The median survival after the diagnosis of GBM ranges from 12 to 15 months (1) .
Despite the identification of numerous genetic alterations in GBM, only a few signaling pathways have emerged as prominent targets of deregulation. Among them is the erbB family of tyrosine kinase receptors, also called HER in humans. This family consists of 4 members: erbB1/EGFR, erbB2/neu, erbB3, and erbB4. erbB receptors are activated by peptide growth factors of the epidermal growth factor (EGF) family. The EGF receptor (EGFR) gene is one of the most frequently altered genes in GBM. Amplification of EGFR is reported in approximately 40% cases and is often associated with rearrangements that lead to the synthesis of constitutively active mutant receptors. All of those deregulations result in excessive activation of the EGFR signaling pathway that promotes proliferation, motility, survival, and resistance to apoptosis of glioma cells (2) . Although there is extensive literature concerning EGFR in glial tumors, relatively few studies have focused on other erbB family members. Overexpression of erbB2 has been reported in variable proportions within GBM (3Y6) and appears to be a marker of poor prognosis (7Y9). Data concerning the neuregulin (NRG) receptors erbB3 and erbB4 in gliomas are even scarcer, but a few studies report their expression in gliomas (10, 11) . Complex interplay between the members of the erbB family is an essential hallmark of this signaling pathway, and the biological response of a cell to an EGF ligand is dependent on the identity of the ligand, the type of erbB dimers that are recruited, and the entire expressed erbB repertoire (12Y15).
ErbB receptors are essential for nervous system development and function. They regulate key processes such as proliferation, self-renewal, and the migration of stem/ progenitor cells; they also regulate their commitment into the major neural lineages (16Y19). The cellular heterogeneity of the CNS is recapitulated in GBM in which tumor cells express astrocytic markers, such as glial fibrillary acidic protein (GFAP), oligodendroglial cell markers, such as the Olig proteins (20Y23), and neuronal markers, such as neurofilament protein and NeuN (24Y27). Moreover, small numbers of cells that express the stem cell marker CD133 and exhibit neural stem cell properties have been identified in GBM (28Y30), suggesting that the phenotypic heterogeneity could arise from aberrant differentiation of tumor stem cells (31) . The erbB receptors are known to be key regulatory elements in the emergence and maintenance of the cellular heterogeneity in the normal CNS, but to our knowledge, their expression in the different phenotypic populations present in GBM has not been explored.
Here, we report a comprehensive analysis of the expression of the entire family of erbB receptors and the 11 EGF peptideYencoding genes in a panel of GBMs compared with that in nonneoplastic cerebral tissue containing neocortex and underlying white matter.
MATERIALS AND METHODS

Tissue Specimens
Specimens of 9 GBMs and 4 adult cerebral cortices were obtained from the Neurosurgery Clinic of the University Hospital of Lille. The tumors were classified and graded by a neuropathologist according to the World Health Organization system (32) . The control samples were nonneoplastic cerebral tissue containing neocortex and adjacent underlying white matter. Clinical details of the controls are listed in Table 1 . The GBM specimens were obtained at initial surgery (n = 7) or were removed at the time of recurrence (n = 2) ( Table 2 ). All specimens were excess brain tissue. Fetal brains between 10 and 12 weeks of age (n = 3) were obtained after elective abortion from the Gynecology Department of the University Hospital of Lille. Residual brain tissue was collected by a multicenter European program of intracerebral transplantation of fetal neurons for the treatment of Huntington disease at the University Hospital of Lille. The tissues were available immediately after sterile retrieval of ganglionic eminences. Written informed consent had been previously obtained from all patients and/or their family members. Permission to use human brain tissue was obtained from the French agency on biomedical research (Agence de la Biomédecine, Saint-Denis la Plaine, France). Immediately after surgery, tissue samples (È0.5 mm 3 Y1 cm 3 ) were rinsed in PBS and cut into small pieces (È0.2Y0.3 mm 3 ). Some pieces were frozen in liquid N 2 for RNA and protein extractions, and some were frozen in Tissue Tek compound for immunohistochemistry (IHC). Samples were stored at j80-C until use.
Clinical Data
On clinical grounds, 8 GBMs were considered to be probably primary and one was probably a secondary GBM. The tumors were considered to be primary when the patient had not had any previous cerebral tumor, when the clinical history was short, and when there was no history of epilepsy. Histological features, such as absence of oligodendroglioma foci or lower-grade foci within the tumor, were also considered in this determination. The patients (7 men, 2 women) had a mean age at diagnosis of 47.8 years (range, 20Y72 years). The mean delay between first symptoms and diagnosis was 38.6 days (range, 15Y90 days). All patients underwent surgery (radical or partial) followed by radiotherapy and/or chemotherapy. The mean follow-up of patients was 17 months; 8 patients developed a recurrence, and one was lost to follow up. The mean period to recurrence was 7.5 months (range, 4Y12 months). Among the 8 remaining patients, 4 underwent a second surgery followed by chemotherapy, and all of them had a second recurrence with a mean delay of 6.2 months after surgery (range, 4Y12 months). Of the 7 patients with a complete follow-up, the mean survival time was 17.7 months (range, 7Y30 months) after the initial surgery date.
Cell Culture
Primary astrocyte cultures from cerebral cortex and the hypothalamus of human fetuses were prepared as previously described (15) . The U251 and U373 human GBM cell lines were cultured in Dulbecco's modified Eagle medium supplemented with 10% (vol/vol) fetal calf serum (Invitrogen, France), 1% (vol/vol) L-glutamine (Invitrogen), and 2% (vol/vol) antibiotics (penicillin/streptomycin; Invitrogen) under a humid atmosphere of 5% CO 2 Y95% air at 37-C. The T98G cell line was cultured in the same medium supplemented with 1% Minimum essential medium nonessential amino acids (Invitrogen). Confluent 10-cm-diameter dishes were used for RNA and/or protein extraction, and poly-L-lysine (Sigma, Saint Quentin Fallavier, France)Ycoated glass coverslips from 24-well plates were used for immunofluorescent labeling.
Real-Time Quantitative RT-PCR
The theoretical basis, primers and polymerase chain reaction (PCR) consumables, RNA extraction, cDNA synthesis, and PCR reaction conditions are described in detail elsewhere (33) . We quantified transcripts of the gene encoding the TATA boxYbinding protein (TBP) as the endogenous RNA control, and each sample was normalized on the basis of its TBP content. Results were expressed as N-fold differences in target gene expression relative to the TBP gene (Ntarget), determined as Ntarget = 2 $Ctsample , where the $Ct value of 
Antibodies
For Western blot analyses, the 4 anti-erbB antibodies used on all samples were rabbit polyclonal antibody antierbB1 from Upstate Biotechnologies (Lake Placid, NY; 1.5 Kg/ml) and rabbit polyclonal antibody anti-erbB2 (sc-284; 1:500), rabbit polyclonal antibody anti-erbB3 (sc-285; 1:100), rabbit polyclonal antibody anti-erbB4 Signaling Biotechnologies (Beverly, MA; rabbit mAb, clone 15F8; 1:1000), anti-erbB2 antibodies from DakoCytomation (Glostrup, Denmark; rabbit polyclonal, Nr. A0485; 1:500) and Novocastra Laboratories (Newcastle Upon Tyne, UK; mouse mAb, NCL-CB11; 1:100), and anti-erbB3 from Upstate Biotechnologies (mouse mAb, clone 2F12; 1:500). Goat polyclonal antibody anti-actin (sc-1616; 1:1000) was from Santa Cruz Biotechnology and the rabbit polyclonal antibody anti-Akt was from Cell Signaling Biotechnologies (1:1000). Horseradish peroxidase-conjugated secondary antibodies were from Sigma.
The antibodies used for immunofluorescence were antierbB1, extracellular domain (mouse mAb, clone 31G7, 1:20; Zymed), rabbit polyclonal antibody anti-erbB2, cytoplasmic domain (No. A0485, 1:250; DakoCytomation), anti-erbB3, cytoplasmic domain (mouse mAb, clone 2F12, 1:50; Upstate Biotechnologies), and anti-erbB4, extracellular domain (mouse mAb, Ab-1, clone H4.77.16, 1:100; NeoMarkers, Fremont, CA). Neural cell types were identified using rabbit polyclonal antibody anti-GFAP (No. Z0334, 1:500; DakoCytomation), mouse anti-GFAP mAb (No. G3893, clone G-A-5, 1:500; Sigma), mouse anti-NeuN mAb, biotin conjugated (MAB377B, 1:100; Chemicon International, Temecula, CA), rabbit polyclonal antibody anti-Olig2 (B119 antiserum, 1:500; gift from Dr H. Chneiweiss INSERM U894, University of Paris 5, Hospital Sainte-Anne, Paris, France), and rabbit polyclonal antibody anti-CD133 (ab16518, 1:50; Abcam, France). The GFAP and NeuN antibodies were used as previously described (27, 34) . The anti-Olig2 antibody was produced and characterized by Dr Chneiweiss. The specificity of the CD133 antibody was verified by Western blot assay, which showed that this antibody yielded a band at the expected molecular weight (È120 kd) in protein extracts from human fetal brain. No signal was detected in extracts of adult human cerebral cortex (data not shown). Proliferating cells were identified using rabbit polyclonal antibody anti-Ki67 (ab15580, 1:100; Abcam). The secondary antibodies used were Alexa 568Yconjugated goat anti-rabbit, Alexa 488Yconjugated goat anti-rabbit, Alexa 568Yconjugated goat anti-mouse, and Alexa 488Yconjugated goat anti-mouse antibodies (1:400; all from Molecular Probes, Eugene, OR).
Specificity of Anti-erbB Antibodies Used for Western Blot Experiments
All anti-erbB antibodies yielded a band at the expected molecular weight (171 kd for erbB1 and 185 kd for erbB2, erbB3, and erbB4) in protein extracts from human fetal and adult brains, primary cultures of human astrocytes, GBM tissues, and cell lines ( Fig Consistent with our previous data (15), the 4 erbB receptors were detected in human fetal brain tissue, erbB3 was undetectable in protein lysates from human fetal hypothalamic astrocyte cultures, and erbB4 was undetectable in protein lysates from human fetal cortical astrocyte cultures ( Fig. 2A) . The specificity of antibodies was further verified using blocking peptides (Figure, Supplemental Digital Content 2, part C, http://links.lww.com/NEN/A116). Anti-erbB1, erbB2, erbB3, and erbB4 antibodies were preincubated for 5 hours at 4-C with a 10-fold molar excess of erbB1 (BP7628b; Abgent, San Diego, CA), erbB2 (sc-284P), erbB3 (sc-285P), and erbB4 (sc-283P) (the latter 3 from Santa Cruz Biotechnology) blocking peptides, respectively, and subsequently immunoblotted with approximately 100-Kg protein extracts from primary cortical astrocyte cultures (for erbB1, erbB2, and erbB3) or fetal brain (for erbB4).
Specificity of Anti-erbB Antibodies Used for Immunofluorescence
In Western blot assay, anti-erbB1, -erbB2, and -erbB3 antibodies yielded a band at the expected molecular weight in protein extracts from primary cortical astrocyte cultures ( 
Immunoprecipitation and Western Blot
Samples were lysed in freshly prepared lysis buffer (25 mmol/L Tris pH 7.4, 50 mmol/L A-glycerophosphate, 1% triton X-100, 1.5 mmol/L EGTA, 0.5 mmol/L EDTA, 1 mmol/L sodium pyrophosphate, 1 mmol/L sodium orthovanadate, 10 Kg/mL leupeptin and pepstatin A, 10 Kg/mL aprotinin, 100 Kg/mL phenylmethylsulfonyl fluoride). For immunoprecipitation of erbB receptors, equal amounts of protein (800Y1000 Kg) contained in a total volume of 750 KL of lysis buffer were incubated with 4 Kg of antibody with gentle rocking overnight at 4-C. Thereafter, 60 KL of protein AYSepharose (Sigma) 1:1 slurry in lysis buffer was added to the antibody-antigen complex and incubated for an additional 4 hours at 4-C. The Sepharose beads were collected by centrifugation, washed twice with ice-cold lysis buffer, and resuspended in 50 KL of 2Â sample buffer. Protein extracts were FIGURE 1. mRNA expression of erbB signaling genes in glioblastomas (GBMs). Real-time quantitative RT-PCR analysis of ERBB genes, their ligands, 3 zinc-dependent matrix metalloproteinases (MMP) (MMP2, MMP9, and ADAM17), and the KI67 cellular proliferation marker in GBM samples (G1YG9). Results are expressed as fold increase in gene expression level in the GBM samples relative to the mean respective expression level in the 4 nonneoplastic cortical tissue samples. Note that although ERBB1 receptor and ligands and ERBB2 receptor mRNA exhibit highly heterogeneous deregulation profiles between tumors, most NRG signaling genes globally show underexpression in the GBM. ADAM, a disintegrin and metalloproteinase; AREG, amphiregulin; BTC, betacellulin; EGF, epidermal growth factor; EPGN, epigen; EREG, epiregulin; HB-EGF, heparin-binding EGF; NRG, neuregulins; TGF>, transforming growth factor>; NE, not expressed.
size-fractionated by sodium dodecyl sulfateYpolyacrylamide gel electrophoresis, as previously described (15, 35, 36) . The membranes were exposed overnight at 4-C to primary antibodies diluted in Tris buffer saline (0.05 mol/L Tris, pH 7.4, 0.15 mol/L NaCl) containing 0.05% Tween 20 and 5% nonfat milk. Protein expression was analyzed by densitometry using the Scion Image software (Scion Corporation, Frederick, MD).
Expression of the erbB receptors for each sample was determined as the densitometric value of the erbB signal divided by the densitometric value of the actin signal revealed on the same membrane. The erbB protein expression values in each GBM sample were subsequently normalized such that the mean expression of the 4 control cortical tissue samples was 1 and were termed fold protein expression (Figs. 2BYI) .
Immunohistochemistry
The Tissue Tek (Sakura Finetek, Villeneuve d'Ascq, France)Yembedded frozen tissues were cut on a cryostat (Leica CM 3050, Nussloch, Germany) in 10-Km-thick sections. The sections were fixed with 1% paraformaldehyde in 0.1 mol/L PBS (pH 7.4) for 15 minutes at room temperature. For erbB2 and CD133 IHC, the sections were first fixed in paraformaldehyde and then immersed for 1 minute in a solution of acetone/methanol 1:1 precooled at j20-C. For Ki67 IHC, the sections were submitted to microwave pretreatment (4 minutes at 800 W followed by 2 cycles 5 minutes each at 400 W in 0.1 mol/L sodium citrate buffer, pH 6) before the IHC procedure. Nonspecific sites were blocked with PBS containing 0.3% Triton X-100 and 2% normal goat serum for 10 minutes at room temperature. Sections were then incubated with antibodies diluted in the same solution. The primary antibodies were applied for 2 nights at 4-C and the secondary antibodies for 1 hour at room temperature. Cell nuclei were stained with Hoechst 33258 bis-benzamidine (1:1000; Molecular Probes). To avoid the strong autofluorescence caused by lipofuscin granules usually present in adult human brain tissue, sections were immersed in a solution of 0.3% Sudan Black B (Sigma) in 70% ethanol for 10 minutes (37) . Control sections were incubated in the absence of primary antibody. Immunolabeling of the human GBM cell lines was performed following the procedure used to label tissue sections. Immunofluorescence was examined on a fluorescent microscope (Imager.Z1, Zeiss, Le Pecq, France) with appropriate filters. Images were acquired using an AxioCam MRm camera (Zeiss) driven by AxioVision software (Zeiss).
IHC Quantitative Analysis
Immunohistochemistry was independently assessed by 3 of the authors (Véronique Duhem-Tonnelle, Vincent Prevot, Ariane Sharif) on the entire surface of 2 to 4 sections per tissue specimen. Quantification of the expression of erbB receptors was made by counting the percentage number of erbB-positive cells over the total number of Hoechst-positive nuclei. Endothelial cells, identified by the small elongated shape of their nuclei, most often lining the border of a cavity, were excluded from the total cell population count. In most GBMs, despite widespread erbB4 immunostaining, absence of erbB4 immunoreactivity in cell bodies precluded quantification of the percentage number of erbB4-expressing cells. Quantification of the expression of erbB receptors in the different cell types was made by counting the percentage number of erbB/GFAP-, Olig2-, NeuN-, or CD133-coexpressing cells over the total number of GFAP-, Olig2-, NeuN-, or CD133-positive cells, respectively. The quantitative analysis was made by performing a double-blind assessment of microphotographs taken at the Â40 objective on several sections of each tissue specimen. A total of 29 to 106 images (n = 6,411 T 1,792 cells) were counted per tissue specimen. In particular, between 29 and 31 images (758Y1,246 cells counted) were analyzed for the quantification of erbB3 and erbB4 expression in each of the control cerebral cortices. Because of the intratumoral heterogeneity of erbB distribution, a higher number of images of the GBM samples were analyzed. Therefore, between 60 and 106 images (1,409Y20,862 cells counted) were analyzed in each of the 9 GBM specimens. To analyze endothelial cell erbB receptor expression, only small and elongated cell nuclei lining the border of a cavity were taken into account.
Statistics
To determine whether the fold erbB expression in tumors relative to control tissues was correlated at the mRNA and protein levels, a linear regression test was performed. The level of significance was set at p G 0.05.
RESULTS
ErbB Receptor mRNA and Protein Expression in Normal Brain and in GBM Tissue ErbB Signaling Gene Expression
Real-time quantitative RT-PCR showed that control cortical tissues expressed the 4 ERBB receptors and all EGF ligands except AREG and EPGN (Table, Supplemental Digital Content 4, http://links.lww.com/NEN/A118). All tumor samples exhibited deregulation in the expression of erbB ligand genes compared with control cortical tissues (Fig. 1 , Table, Supplemental Digital Content 4, http://links.lww.com/ NEN/A118). Although EPGN was not detected in any GBM, as in the control cortices, AREG mRNA expression was found in 5 of 9 tumor samples. The other erbB1 ligand genes (EGF, TGFa, HB-EGF, BTC, EREG) exhibited highly heterogeneous expression profiles ranging from underexpression to overexpression, depending on the tumor. In contrast, most NRG genes (NRG2, NRG3, and/or NRG4) were downregulated in GBM samples. All 4 ERBB mRNA were detected (BYE) Densitometric analysis of erbB1 (B), erbB2 (C), erbB3 (D), and erbB4 (E) protein expression in the 4 control cortical tissues (cortex) and the GBM samples. x axis, sample number. Results are expressed as fold increase in protein expression for each GBM sample (black columns) relative to the mean respective erbB protein expression in the 4 nonneoplastic cortical tissues (white columns). Horizontal solid line, mean erbB protein expression in the control samples normalized to 1. Note that erbB1 and erbB2 receptors exhibit highly discrepant expression profiles among GBM samples; erbB3 and erbB4 protein contents are consistently downregulated. (FYI) For each erbB receptor, the fold mRNA expression values were compared with the respective fold protein expression values across the glioblastoma cohort using a linear regression test. Note the overall correlation between mRNA and protein levels of erbB receptors in tumors relative to control cortices.
in each tumor sample. ERBB1 and ERBB2 mRNA expression was highly variable among samples (ranging from underexpression to overexpression), but the 2 NRG receptors, ERBB3 and ERBB4, showed marked underexpression in most GBMs. Genes encoding the 2 zinc-dependent matrix metalloproteinases MMP2 and MMP9, which are involved, at least in part, in ectodomain shedding of erbB ligands (38) , were strongly overexpressed in most GBM samples. All tumors exhibited marked overexpression of the cellular proliferation marker KI67 gene, indicating the proliferative nature and absence of massive necrosis in the samples analyzed (39, 40) .
Western Blot Analysis of erbB Receptor Protein Expression
As previously reported (15), the 4 erbB receptors were detected in human fetal brain. Consistent with our previous findings, primary cultures of human fetal cortical astrocytes lacked erbB4 expression, whereas fetal hypothalamic astrocytes were devoid of erbB3 protein ( Fig. 2A) . All 4 erbB receptors were detected in adult cerebral cortex tissues, albeit at varying levels between samples (Figs. 2A, lanes C1 to C4, and BYE, white bars).
The erbB1 and erbB2 receptors were expressed in all GBMs, whereas erbB3 and erbB4 proteins were detected in 7 of 9 and 8 of 9 GBM samples, respectively ( Fig. 2A, lanes  G1YG9) . The samples exhibited a wide range of erbB1 and erbB2 expression strengths, with GBM having lower, similar, or higher protein levels than the mean erbB1 and erbB2 content in the control tissues, respectively (Figs. 2AYC). Only 2 tumors (G1 and G6) exhibited erbB1 protein overexpression compared with the mean expression in control samples. There was a positive correlation between erbB1 and erbB2 expressions both at the protein (r 2 = 0.87; linear regression, p G 0.001) and at the mRNA (r 2 = 0.92; linear regression, p G 0.001) levels in the GBMs. The erbB3 and erbB4 receptors were underexpressed in GBMs compared with control cortices (Figs. 2A, D, E) . The erbB protein expression profiles in the GBM and cortical tissues were further confirmed by Western blot analysis using a different battery of anti-erbB antibodies ( All 3 human GBM cell lines tested expressed erbB1 and erbB2 at the protein and mRNA levels; none of them expressed erbB3 or erbB4 ( Fig. 2A Altogether, these results show that expression of ERBB signaling genes is deregulated in GBM tissues compared with control cortices. The erbB1 receptor and ligands and the erbB2 receptor exhibited highly heterogeneous deregulation profiles among tumors, but overexpression of erbB1 and erbB2 was limited to a minority of tumors, whereas most NRG receptors and ligands showed underexpression in the GBM.
ErbB Receptor Cellular Distribution in the Cerebral Cortex and in GBM Adult Cerebral Cortex
All cerebral cortical samples showed similar immunoreactivity profiles for the erbB receptors and the GFAP, NeuN, and Olig2 cell markers. The control cerebral cortices stained negatively for erbB1 and erbB2. Strong erbB3 immunostaining was detected in 92.8% T 2.7% NeuN-positive cells (Figs. 3AYC) , in a large fraction of Olig2-positive cells both in gray and white matter (64.1% T 12.8% and 65.6% T 2.0%, respectively, Figs. 3DYF) and in 72.4% T 9.9% of GFAP-positive astrocytic cell bodies (Figs. 3GYI) . erbB4 expression was only detected in NeuN-positive cells and was restricted to a small fraction of this cell population (18.7% T 6.0%, Figs. 3JYL). In contrast to erbB3 immunostaining that was limited to the proximal part of neurites (Fig. 3A) , erbB4 staining extended along neuronal processes with a punctate appearance (Fig. 3J) .
Glioblastoma
Immunostaining for GFAP, NeuN, and Olig2 in the GBM had distinct aspects compared with nonneoplastic cerebral cortices, and staining patterns were highly heterogeneous both between and within tumors. The dense network of GFAP-positive thick filaments (Figs. 4B , 5B) was additionally dotted with numerous hypertrophic astrocytes in 4 samples (Figs. 6B, 7B ). Olig2-positive and NeuN-positive nuclei exhibited marked heterogeneity in their densities, distributions, sizes, and shapes (Figs. 4E, 5E, H, 6E, H, 7E). The NeuN immunostaining was reminiscent of that in the nonneoplastic cortex in 2 GBMs (Figs. 5H inset, 6H main panel).
ErbB1
ErbB1-positive cells were seen in all GBMs at highly variable densities both between (Fig. 4G ) and within tumors. erbB1-positive cells were distributed as scattered isolated cells (Fig. 4A) or as dense clusters of various sizes (Fig. 4D) . Consistent with the Western blot analysis, the strongest immunoreactivity for erbB1 was seen in 2 samples, G1 and G6, in which there was intense staining of most cells (Fig. 4G) . erbB1 was expressed in relatively large fractions of GFAPpositive (Figs. 4AYC, H) and Olig2-positive (Figs. 4DYF, H ) cells in 9 of 9 and 8 of 9 tumors, respectively. In contrast, coimmunolabeling of erbB1 and NeuN was seen in only 2 samples and was restricted to a small fraction of the NeuNpositive cell population (Fig. 4H ).
ErbB2
ErbB2 immunoreactivity was detected in all GBMs in variable proportions of cells between tumors (Figs. 5A, D , G, J). Colocalization of erbB2 with GFAP (Figs. 5AYC) , Olig2 (Figs. 5DYF) and NeuN (Figs. 5GYI) was seen in 6 of 9, 4 of 9, and 1 of 9 GBMs, respectively, and was globally limited to small populations of cells (Fig. 5K) . The erbB2 was preferentially coexpressed with GFAP and Olig2 across the GBMs (n = 7/9 samples). However, erbB2 distribution among the 3 neural cell types was heterogeneous. Only 3 GBMs expressed erbB2 both in GFAP-positive and Olig2-positive cell populations. None of them expressed erbB2 in all 3 cell types. 
ErbB3
ErbB3 immunoreactivity was detected in all GBMs; most tumors exhibited erbB3 immunoreactivity on most or all of the tissue in variable proportions of cells (Figs. 6A, D, G, J) .
Notably, the 2 samples that expressed ERBB3 mRNA but lacked detectable erbB3 protein by Western blot (G5 and G6; Figs. 2A, D) showed a highly heterogeneous density of erbB3-positive cells across the tissue with large areas devoid of staining. erbB3 expression was detected in relatively large fractions of the GFAP-positive (Figs. 6AYC) , Olig2-positive (Figs. 6DYF) , and NeuN-positive populations (Figs. 6GYI) in 6 of 9, 7 of 9, and 6 of 9 tumors, respectively (Fig. 6K) . erbB3-positive cells exhibited heterogeneous sizes and shapes (Figs. 6AYI) . erbB3/GFAP-coexpressing cells corresponded to hypertrophic reactive astrocytes (Figs. 6AYC, right) or to small irregular cells (Figs. 6AYC, left) . Consistent with previous reports (42, 43) , only a few scattered cells were Ki67-positive in tumors. Notably, all Ki67-positive cells also expressed erbB3 (Figs. 6A 1 YC 1 ).
ErbB4
Consistent with Western blot data, erbB4 immunoreactivity was not detected in the G5 sample. In all erbB4-positive GBMs, the staining appeared as bright punctate labeling of fine cell processes, as in neuronal elements of the cerebral cortex (Figs. 7AYC, arrowheads) , but densities of immunoreactive cell processes were highly variable in the GBM. Rare erbB4/NeuN-coexpressing cell bodies were seen in 3 tumors (Figs. 7DYF inset, G) . One GBM (G4) exhibited an atypical expression profile, with areas of a dense network of erbB4-positive cell processes devoid of the usual punctate appearance, associated with numerous NeuN-positive nuclei of heterogeneous sizes and shapes (Figs. 7DYF, main panel) . erbB4 immunoreactivity was also detected in small subsets of GFAP-positive hypertrophic astrocytes in 3 of 8 GBMs (Figs. 7AYC, G) . No Olig2-positive cells showed erbB4 immunoreactivity (Fig. 7G) .
ErbB1, erbB2, and erbB3, but not erbB4, were also detected in endothelial cells in 5 of 9, 6 of 9, and 7 of 9 GBMs, respectively. Most tumors (6/9) contained both erbBpositive and erbB-negative blood vessels (data not shown).
Altogether, these results show that erbB1 and erbB2 are preferentially detected in the GFAP-positive and Olig2-positive cell populations in GBM, albeit with different distribution profiles. erbB3 is expressed in significant fractions of GFAP-positive, Olig2-positive, and NeuN-positive cells, whereas erbB4 mainly exhibits a Bneuronal-type[ expression profile. Both NRG receptors are occasionally seen in small subsets of hypertrophic astrocytes.
GBM Cell Lines
The U251 and U373 cell lines were strongly GFAP pos- 
ErbB1 and erbB3 Receptors but Not erbB4 Receptors Are Expressed in CD133-Immunoreactive Cells
We performed double IHC staining of CD133 and erbB1, erbB3, or erbB4 to evaluate the erbB ligand responsiveness of the population of CD133-positive cells in GBMs. CD133 immunoreactivity was detected in small populations of cells in 7 of 9 GBMs (Figs. 8B, E, G) . Those cells were seen in restricted tumor areas and often appeared as clusters, with some located at the vicinity of blood vessels (Fig. 8B) . In all CD133-positive tumors, erbB3 was detected in most CD133-positive cells (Figs. 8DYF, H) . In 6 of 7 samples, CD133-positive cells were erbB1 positive (Figs. 8AYC) , but the extent of erbB1 expression was limited to a small fraction of the CD133-positive cell component (Fig. 8H) . erbB4 was never detected in CD133-positive cells (Fig. 8H) . Altogether, these results show that most of the GBMs contain CD133-positive cells potentially able to respond to all erbB ligands. Although a limited fraction of the CD133-positive cell population can respond to erbB1 ligands, most of this population can respond to NRG. Interestingly, some CD133-positive cells were also seen in restricted zones of the peritumoral cortical sample, at the margin of the resected glioma. Noticeably, they were also erbB3 positive (data not shown).
DISCUSSION
We have shown that most erbB ligands and receptors are deregulated in GBMs compared with control cortices and that each erbB receptor exhibits a distinct distribution profile among the main neural cell types expressed in GBMs. In particular, whereas overall erbB3 expression is downregulated in tumors, this receptor is prominently expressed in CD133-positive putative tumor stem cells. This suggests that erbB3 may be important in cancer stem cell biology and may thus represent a new candidate for targeted molecular therapy. 
Methodological Considerations in the Analysis of erbB Receptor Expression
There was an overall positive correlation between erbB receptor mRNA expression and protein levels, but there were some discrepancies between protein expression data obtained by Western blot analysis and those obtained by IHC. Two GBMs contained both erbB3 mRNA and erbB3-positive cells, whereas no signal was detected on immunoblots. Because the distribution of erbB3 immunoreactivity was more heterogeneous in these samples than in the others, it is possible that the analysis of different tissue pieces from the same tumor might have resulted in the discrepancy. Our finding that by IHC all FIGURE 7. ErbB4 immunoreactivity is preferentially distributed in neuron-like elements in the glioblastomas (GBMs) and is also occasionally detected in hypertrophic astrocytes. (AYF) Double immunofluorescent labeling of erbB4 (green) with glial fibrillary acidic protein (GFAP) (red) or NeuN (red). erbB4 immunoreactivity mainly appeared as a bright punctate staining of fine cell processes (AYC, arrowheads). Rare erbB4/NeuN-coexpressing cells were detected in some tumors (DYF, inset). An atypical immunostaining profile consisting of numerous erbB4 weakly immunoreactive cell processes deprived of the usual punctate aspect (DYF, main panel, arrows) was seen in a GBM in association with abnormal NeuN-positive nuclei. erbB4 immunoreactivity was occasionally detected in GFAP-positive hypertrophic astrocytes (AYC, arrows). erbB4 immunolabeling did not exhibit a punctate aspect in GFAP-positive soma and cell processes. Nuclei were counterstained with Hoechst (blue). Scale bars = 20 Km. GBM specimens contained erbB1-positive and erbB2-positive cells whereas control cortical tissues lacked detectable erbB1 and erbB2 immunoreactivity suggests that both receptors are overexpressed in GBM. Immunoblotting experiments using the same antibodies as those used for IHC (as well as a battery of other anti-erbB1 and -erbB2 antibodies) showed that most tumors expressed levels of erbB1 and/or erbB2 protein similar to or lower than those in control tissues. This indicates that increased immunoreactivity is not an absolute indicator of protein overexpression. The dimerization and activation status of erbB receptors influence receptor conformation (44, 45) and hence may modify their antigenicity. Besides the welldocumented constitutive activation of the EGFRvIII mutant receptor (46) , increased tyrosine phosphorylation of wild-type erbB1 (47) , erbB2 (48, 49) , and erbB3 receptors (50) has been reported in glioma biopsies and cell lines. Therefore, in the absence of gene amplification, the increased immunoreactivity for erbB receptors in GBM may indicate a higher activation status and/or modified dimerization profile rather than overexpression at the protein level. Indeed, most studies of erbB receptor expression in gliomas have used IHC techniques. Quantitative data are nonetheless available concerning ERBB1 gene amplification, which is detected in approximately 40% of GBMs and leads to increased erbB1 mRNA levels (51) . It should be mentioned that despite the small number of samples analyzed, overexpression of erbB1 mRNA was detected in 4 (44%) of 9 of our GBMs. Comparing immunostaining data with the quantitative evaluation of erbB expression levels may be informative when interpreting the molecular profiles of tumors. Indeed, although high-throughput profiling using microarrays can reveal molecular signatures, it may fail to reveal highly immunoreactive tumors that exhibit hyperactive erbB signaling because of low expression levels.
Expression of erbB Receptors and Ligands Is Deregulated in GBMs
Quantitative RT-PCR revealed substantial heterogeneity in the deregulation profiles of erbB ligand mRNAs between samples. The development of autocrine/paracrine loops through the combined overexpression of erbB receptors and ligands is a mechanism commonly used by tumoral cells to promote cancer growth. Several human glioma cell lines are known to display TGF>/erbB1Y or HB-EGF/erbB1Y driven autocrine loops with a growth-promoting action that can be inhibited by neutralizing antibodies directed against the ligands (52Y54). In our series, all GBMs that had upregulation of erbB1 mRNA levels also showed increased expression of one or several erbB1 ligands, thereby demonstrating the molecular components that allow for the establishment of a growth-promoting autocrine/paracrine loop. The determination of both EGF ligand and receptor repertoires may thus help to identify gliomas that use erbB trophic loops to enhance their tumorigenicity.
The GBM erbB receptor expression and IHC profiles were highly heterogeneous. The detection of the 4 erbB receptors in GBM with highly variable expression levels between samples is in agreement with previous studies (5, 10, 11, 55Y58) . Despite this heterogeneity, we found certain preferential phenotypic profiles among erbB-positive cells. Both erbB1 and erbB2 were preferentially expressed in GFAP-positive and Olig2-positive cells and coexpression with NeuN was rare. Although erbB1 was detected in both the GFAP-positive and Olig2-positive compartments in most tumors, the distribution of erbB2 varied between these 2 cell types and did not exhibit any preferential profile. Thus, although the mRNA and protein levels of erbB1 and erbB2 were positively correlated overall, a correlation was not seen in their cellular distribution. erbB3 immunoreactivity was detected in significant fractions of the GFAP-positive, Olig2-positive, and NeuN-positive populations in the GBMs. Although erbB3 was expressed in the 3 cell types in the control cerebral cortex samples, erbB3 distribution pattern was restricted to 1 or 2 neural cell types in most tumors. Moreover, the extent of erbB3 expression among these neural cell types was more limited in tumors than in control samples. Because GFAP and Olig2 are not only expressed in mature glial cells but also in neural stem cells/progenitors (59, 60) , the GFAP-positive and Olig2-positive cells may correspond to undifferentiated cells within tumors. Importantly, because GFAP, Olig2, and NeuN are expressed both in the normal CNS and in tumoral cells, labeling with these markers does not allow tumoral elements to be distinguished from nonneoplastic endogenous cells trapped within the tumors. Noticeably, some erbB3/GFAP-coexpressing cells strongly resembled nonneoplastic hypertrophic reactive astrocytes. erbB1, erbB2, and erbB3 immunoreactivity was, however, mostly detected in GFAP-positive, Olig2-positive, and/or NeuN-positive cells with abnormal sizes and shapes, and erbB immunoreactivity was also detected in Ki67-positive cells, thereby arguing for their tumoral nature. Thus, the primary expression of erbB1, erbB2, and erbB3 receptors in nonneoplastic elements trapped within primary tumors seems unlikely. In contrast, the staining pattern of erbB4 in GBMs mainly resembled that observed in neurons of the normal cortex. In addition, erbB4 immunoreactivity was seen in subsets of hypertrophic reactive astrocytes within some tumors, as reported by others (11) . Therefore, our observations suggest that, in most cases, erbB4 may not be expressed by tumoral elements and may not play a prominent role in the GBM cell biology.
Although erbB1, erbB2, and most EGF ligands were detected in the 3 human GBM cell lines, there were discrepancies between cell lines and the tumors in their erbB receptor and ligand expression profiles. In particular, whereas erbB3 and erbB4 were expressed in most primary tumors, these receptors were not detected in the cell lines, as described by others (10) . In contrast to primary tumors that contain heterogeneous populations, these cell lines are homogeneous populations and we failed to detect Olig2, NeuN, and CD133 in the cell lines examined, possibly because of our culture conditions. Thus, the cell lines did not recapitulate the heterogeneous profiles of the primary tumors, and the absence of these different tumor subpopulations in our cultures might explain the lack of erbB3 expression in the cell lines, a possibility that will require further investigation. Noticeably, immunostaining of erbB3 in primary tumors showed that all erbB3-positive specimens contained both erbB3-positive and erbB3-negative tumor cell populations, raising the possibility that erbB3-negative cell lines might be derived from these tumors. Interestingly, our observation that erbB4 immunoreactivity in tumor biopsies was mostly seen in nontumoral elements is in agreement with the lack of erbB4 expression in the cell lines.
Expression of erbB Receptors in the CD133-Positive Cell Population
We found that CD133-positive cells express specific members of the erbB receptor family. Although erbB4 was never detected in this population, erbB1 and erbB3 were found in some CD133-positive cells. erbB1 plays key roles in the control of the proliferation, differentiation, survival, and migration of neural stem cells and progenitors within the normal CNS (16) . Recent studies have shown that tumor-initiating cells isolated from human GBMs express erbB1 in vitro and require the activation of erbB1 signaling for self-renewal and proliferation (61, 62) . These studies have also demonstrated that several erbB1 kinase inhibitors (e.g. AG1478, gefitinib, erlotinib) inhibit proliferation and induce apoptosis in cancer stem cells in vitro. Our study indicates that erbB1/CD133-coexpressing cells are indeed present in GBMs. These cells were, however, not detected in all tumors, and when present, they represented only a small fraction of the CD133-positive population, suggesting that inhibitors of erbB1 signaling would only target a limited number of cancer stem cells in vivo. On the other hand, the expression of erbB3, and hence the ability to respond to NRG, occurred in most of CD133-positive cells in all CD133-positive GBMs. The CD133-positive cell population only accounted for 7.2% T 1.8% of the total cell population and was located within discrete areas of the tumors. Therefore, the erbB3 protein content of the CD133-positive cell population might not have had a significant impact on the global erbB3 protein content of large tissue pieces, thus explaining why erbB3 was underexpressed in GBMs as a whole compared with control cortices despite its prominent expression in the CD133-positive cell fraction. Although NRG1 has been shown to promote the proliferation and survival of neural stem cells/progenitors (63) , the consequences of the activation of NRG/erbB3 signaling in cancer stem cells remain to be explored. Interestingly, we saw CD133/erbB3-coexpressing cells in areas of the peritumoral cortical sample corresponding to the margin of the resected glioma. The observation of CD133-positive cells in the macroscopically nonneoplastic peritumoral cortex raises the possibility that these tumor cells migrate to initiate tumor recurrences. Whether erbB3 signaling is involved in the migratory properties of these putative cancer stem cells has yet to be determined.
Although inhibitors of erbB1 and erbB2 signaling have significantly improved the survival of patients with several types of cancers, their efficacy in gliomas remains limited (64) . Studies conducted on breast cancer, gastric cancer, and glioma cell lines have shown that tumor cells escape the proapoptotic and antiproliferative effects of inhibitors of erbB1 and erbB2 signaling by the activation of the erbB3/ PI3K/Akt pathway (65Y67). Efficient recovery of the proapoptotic effect is observed upon siRNA-mediated gene knockdown of erbB3 expression (67) . These data, along with our present visualization of erbB3 immunoreactivity in most GBM cell types (and particularly in the CD133-positive population), suggest that it may be important to assess erbB3 expression in GBMs and that targeting this receptor, in association with other molecules, may be a therapeutic strategy of interest.
In conclusion, the present study provides the first assessment of erbB expression in the main neural cell types present in GBMs, particularly in CD133-positive putative tumor stem cells. Although the determination of global mRNA and protein content may be useful in defining molecular signatures, the identification of the nature of erbBpositive cells within tumors could provide insights into the possible involvement of erbB receptors in the biology of GBMs and yield valuable information for the development of therapeutic strategies.
